moxonidine (Moxon)

01/01/2005 - "[Clinicogenetic aspects of carbohydrate metabolism disorders and efficacy of their correction with moxonidine and metformine in patients with arterial hypertension]."
01/01/2005 - "Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients."
01/01/2002 - "To assess efficacy of monotherapy with moxonidine in female patients with hypertension and climacteric syndrome. "
08/01/2001 - "Safety and efficacy of moxonidine in mild to moderate hypertension."
02/01/2016 - "Moxonidine acts centrally to reduce activity of the SNS, and clinical trials indicate that this is associated with a decreased AF burden in hypertensive patients with paroxysmal AF and reduced post-ablation recurrence of AF in patients with hypertension who underwent pulmonary vein isolation (PVI). "

01/01/2006 - "Sympathetic activity commonly is increased in obese hypertensive patients, and moxonidine is effective in lowering BP and improving insulin sensitivity. "
01/01/2018 - "Anti-inflammatory effects of moxonidine and a relationship between insulin resistance and sympathetic response to moxonidine are suggested which need to be further explored. "
01/01/2018 - "There was a significant association between markers of insulin resistance at baseline and reduction in sympathetic activity with moxonidine. "
02/01/2007 - "Chronic but not acute moxonidine treatment partially restores insulin sensitivity in SHROB adipocytes, suggesting an indirect action of this agent."
02/01/2007 - "Marked insulin resistance in obese spontaneously hypertensive rat adipocytes is ameliorated by in vivo but not in vitro treatment with moxonidine."

01/01/2013 - "While the observed trend towards improvement in various metabolic parameters merits further investigation, the overall effect of moxonidine treatment is consistent with a reduction of total cardiovascular risk in this hypertensive metabolic syndrome cohort."
01/01/2023 - "Moxonidine ameliorates cardiac injury in rats with metabolic syndrome by regulating autophagy."
01/01/2013 - "This study was designed to assess the effects of moxonidine on blood pressure and aspects of the metabolic syndrome in racially diverse population of patients encountered in routine medical practice. "
10/01/2013 - "Also, moxonidine has beneficial effects in obese and metabolic syndrome and in target-organs, such as heart and kidneys. "
06/01/2011 - "The aim of our non-interventional observational clinical study was to evaluate the safety of treatment with moxonidine and to assess changes to the metabolic syndrome-related laboratory parameters. "

01/01/2001 - "To study effectiveness and safety of physiotens in elderly patients with essential hypertension (degree 1-2). "
01/01/2006 - "Moxonidine: a review of its use in essential hypertension."
06/01/2003 - "In a randomized, double-blind fashion, 35 patients with mild to moderate essential hypertension received placebo run-in medication for 2 weeks, followed by 4 weeks' moxonidine sustained release (1.5 mg o.d.) or placebo. "
06/01/2000 - "Evidence exists for a state of sympathetic hyperactivity in essential hypertension, and moxonidine, a new central sympathetic inhibitor, has been introduced for its treatment. "
12/01/1991 - "Moxonidine has favorable effects on hemodynamics and the neurohumoral system in patients with essential hypertension and is well tolerated at the dose administered."

11/01/2013 - "Moxonidine-induced central sympathoinhibition attenuated brain oxidative stress, prevented cardiac dysfunction and remodelling, and improved the prognosis in rats with hypertensive heart failure. "
10/01/2003 - "Nonetheless, the excess early mortality and morbidity suggest the likelihood of an adverse effect of moxonidine SR and raise concerns regarding the efficacy of generalized sympathetic inhibition in heart failure."
11/01/2013 - "In the present study, we investigated the effects of central sympathoinhibition by intracerebral infusion of moxonidine on survival in a rat model of hypertensive heart failure and the possible mechanisms involved. "
11/01/2004 - "The MOXonidine CONgestive Heart Failure trial was a randomized comparison of moxonidine, a central sympathetic inhibitor, with placebo. "
11/01/2013 - "Intracerebroventricular (ICV) infusion of moxonidine (moxonidine-ICV-treated group [Mox-ICV]) or vehicle (vehicle-ICV-treated group [Veh-ICV]) was performed at 14-20 weeks of age, during the increased heart failure phase. "